Tag: treatments for carcinoid
15 Videos from the 3rd Theranostics World Congress
The 3rd Theranostics World Congress featured a patient education day on Saturday, March 14, made possible with support from the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation. The NorCal CarciNET Community provided funding to…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting
Josh Mailman, President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…
READ MORE
A Possible Cure for Neuroendocrine Cancer: Exciting Update!
Back in September 2012 we shared the following: “For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor. At Uppsala University in Sweden researchers are ready to start a …
READ MORE
2012 CNETS Canada Carcinoid and Neuroendocrine Conference Joins Medical Professionals, Patients & Caregivers
Carcinoid cancer and neuroendocrine tumor specialists from around the world, fascinating presentations on all aspects of these rare diseases, the opportunity to meet fellow carcinoid and neuroendocrine tumor (NETs) patients and caregivers from…
READ MORE
California Carcinoid and Neuroendocrine Tumor Conference Scheduled for January
Carcinoid and neuroendocrine tumor patients and their families are invited to attend the 2012 NET Patient Half Day Conference on Sunday, January 22 in San Francisco, California. The latest developments in NET cancers, including clinical trials, …
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
